

Financial Supervision Authority

Current report No. 46/2018

Date prepared: 21/06/2018

Abbreviated name of the issuer:

Mabion S.A.

Subject

Acceptance for evaluation of marketing authorization application for MabionCD20 drug by the European Medicines Agency.

Legal basis

Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information.

Content of the report:

With reference to the current report no. 36/2018 dated on June 1, 2018, the Management Board of Mabion S.A. (“the Company“) informs that on June 21, 2018 it received information about successful completion of validation of the marketing authorization application (MAA) for a drug under a working name “MabionCD20” by the European Medicines Agency (EMA) and thus its admission to the evaluation procedure.

The Company informs that the confirmation of the application for evaluation acceptance, referred to in the above-mentioned report, does not guarantee product approval by the European Medicines Agency.